DETALIMOGENE VORAPLASMID:

An investigational, non-viral gene therapy designed for bladder-localized immune activation in non-muscle invasive bladder cancer

THE DDX® PLATFORM allows for **intravesical delivery of plasmid DNA to mucosal tissues**, with localized exposure and minimal systemic distribution[1,2]

The DDX® platform enables consistent, industrial-scale manufacturing of a **non-viral, lyophilized drug product**[1,2]





DETALIMOGENE VORAPLASMID is a non-viral gene therapy designed to drive **durable tumor control through synergistic stimulation of specific innate and adaptive immune responses**

Detalimogene **delivers plasmid DNA** encoding 3 immune stimulatory genes, **RIG-I agonists, and IL-12**, to the bladder urothelium, inducing local transgene expression[2-5]





RIG-I ACTIVATION simulates a viral infection, triggering innate immune signaling and **recruitment of antitumor NK and T cells**[2,3]

LOCALIZED IL-12 EXPRESSION drives **Th1 polarization of tumor-infiltrating T-cells, antitumor cytokine production, and immune memory formation**[2,3,5]

DETALIMOGENE HAS DEMONSTRATED DURABLE BLADDER-LOCALIZED ANTITUMOR IMMUNITY IN ANIMAL MODELS[3]

DDX, delivery DNA complex; IL-12, interleukin 12; NK, natural killer; RIG-I, retinoic acid–inducible gene I; Th1, T helper type 1.

1. Panicker R, et al; enGene, Inc., assignee. Patent WO2020/183238 A1. September 17, 2020. 2. Joshi S, et al. Presented at: 2025 ASCO GU Cancers Symposium; February 13-15, 2025; San Francisco, CA. Abstract TPS886. 3. Narayan VM, et al. Poster presented at: 2025 ASCO GU Cancers Symposium; February 13-15, 2025; San Francisco, CA. Abstract 826. 4. Taylor J, et al. Presented at: 2025 ASCO GU Cancers Symposium; February 13-15, 2025; San Francisco, CA. Abstract 802. 5. Steinberg JD, et al. Presented at: 2023 SUO; November 28-December 1, 2023; Washington, DC. Abstract 112.

This document contains medical information concerning a mechanism still under investigation.

©2026 enGene Inc. All rights reserved. February 2026.

enGene